EE05270B1 - Mittekristallilise kaltsiumatorvastatiini valmistamismeetod - Google Patents

Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Info

Publication number
EE05270B1
EE05270B1 EEP200300333A EEP200300333A EE05270B1 EE 05270 B1 EE05270 B1 EE 05270B1 EE P200300333 A EEP200300333 A EE P200300333A EE P200300333 A EEP200300333 A EE P200300333A EE 05270 B1 EE05270 B1 EE 05270B1
Authority
EE
Estonia
Prior art keywords
atorvastatin
crystalline
calcium
oratorvastatin
preparation
Prior art date
Application number
EEP200300333A
Other languages
English (en)
Estonian (et)
Inventor
Sorsak Gorazd
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of EE200300333A publication Critical patent/EE200300333A/xx
Publication of EE05270B1 publication Critical patent/EE05270B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200300333A 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod EE05270B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium

Publications (2)

Publication Number Publication Date
EE200300333A EE200300333A (et) 2003-10-15
EE05270B1 true EE05270B1 (et) 2010-02-15

Family

ID=20432812

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300333A EE05270B1 (et) 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Country Status (27)

Country Link
US (2) US6750353B2 (cs)
EP (1) EP1373202B1 (cs)
JP (1) JP4336106B2 (cs)
KR (1) KR100882066B1 (cs)
CN (1) CN1260213C (cs)
AT (1) ATE294159T1 (cs)
AU (1) AU2002219455B2 (cs)
BG (1) BG108017A (cs)
BR (1) BR0206637A (cs)
CA (1) CA2435954C (cs)
CZ (1) CZ20031988A3 (cs)
DE (1) DE60203894T2 (cs)
DK (1) DK1373202T3 (cs)
EE (1) EE05270B1 (cs)
ES (1) ES2240748T3 (cs)
HR (1) HRP20030575B1 (cs)
HU (1) HU227535B1 (cs)
IL (2) IL157068A0 (cs)
MX (1) MXPA03006548A (cs)
PL (1) PL209428B1 (cs)
RS (1) RS51010B (cs)
RU (1) RU2324679C2 (cs)
SI (2) SI20814A (cs)
SK (1) SK286593B6 (cs)
UA (1) UA73829C2 (cs)
WO (1) WO2002059087A1 (cs)
ZA (1) ZA200305307B (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
AU2002216359A1 (en) * 2001-02-27 2002-09-12 Council Of Scientific And Industrial Research Essential oil composition for potable water disinfection
HUP0400381A2 (hu) 2001-06-29 2004-09-28 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
WO2005033078A1 (en) * 2003-10-07 2005-04-14 Biocon Limited Process for the production of atorvastatin calcium
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
JP4422488B2 (ja) 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
CA2520740C (en) 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
KR20060026121A (ko) 2003-07-02 2006-03-22 에지스 지오기스제르기아르 알티. 혈소판 응집 억제 약물의 무정형 형태를 제조하는 방법
WO2005005384A1 (en) * 2003-07-15 2005-01-20 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2551549A1 (en) * 2003-12-29 2005-07-14 Lek Pharmaceuticals D.D. Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
EP3581564A1 (en) 2004-05-05 2019-12-18 Pfizer Products Inc. Diethylamine salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
EP1784389A4 (en) * 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2007088553A1 (en) * 2006-01-31 2007-08-09 Jubilant Organosys Limited Process for the preparation of amorphous atorvastatin calcium salt
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
BRPI0818575A2 (pt) * 2007-10-17 2014-10-07 Todd F Ovokaitys Processo para a modificação do estado sólido de um composto e composições co-amorfas produzidas com o mesmo
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CN103108863B (zh) * 2010-04-19 2015-08-19 中化帝斯曼制药有限公司荷兰公司 低醚杂质的阿托伐他汀的制备
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法
CA3201604A1 (en) 2020-12-08 2022-06-16 Todd Frank OVOKAITYS Methods and systems for increased production of stem cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
BR9609872A (pt) * 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (cs) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
UA73829C2 (en) 2005-09-15
US20030109569A1 (en) 2003-06-12
DE60203894T2 (de) 2006-01-19
US7074940B2 (en) 2006-07-11
AU2002219455B2 (en) 2007-04-26
RU2003124962A (ru) 2005-01-10
ATE294159T1 (de) 2005-05-15
EP1373202B1 (en) 2005-04-27
HUP0302797A3 (en) 2009-09-28
SK286593B6 (sk) 2009-01-07
HU227535B1 (en) 2011-08-29
SI1373202T1 (sl) 2005-12-31
JP4336106B2 (ja) 2009-09-30
CZ20031988A3 (cs) 2003-11-12
MXPA03006548A (es) 2004-10-15
SI20814A (sl) 2002-08-31
RU2324679C2 (ru) 2008-05-20
CA2435954C (en) 2008-06-03
BR0206637A (pt) 2004-08-03
SK9082003A3 (en) 2003-12-02
US6750353B2 (en) 2004-06-15
CA2435954A1 (en) 2002-08-01
US20040072895A1 (en) 2004-04-15
IL157068A (en) 2009-09-01
JP2005503997A (ja) 2005-02-10
EP1373202A1 (en) 2004-01-02
KR100882066B1 (ko) 2009-02-10
CN1260213C (zh) 2006-06-21
PL209428B1 (pl) 2011-08-31
RS51010B (sr) 2010-10-31
HRP20030575A2 (en) 2005-06-30
WO2002059087A1 (en) 2002-08-01
ES2240748T3 (es) 2005-10-16
CN1487921A (zh) 2004-04-07
DE60203894D1 (de) 2005-06-02
BG108017A (bg) 2004-08-31
YU56803A (sh) 2006-05-25
PL361763A1 (en) 2004-10-04
ZA200305307B (en) 2004-07-09
HRP20030575B1 (hr) 2011-10-31
KR20030077003A (ko) 2003-09-29
HUP0302797A2 (hu) 2003-11-28
DK1373202T3 (da) 2005-05-17
IL157068A0 (en) 2004-02-08
EE200300333A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
EE200300333A (et) Mittekristallilise kaltsiumatorvastatiini valmistamismeetod
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
DK0891325T3 (da) Para-substituerede phenylpropansyrederivater som integrinantagonister
BG103945A (bg) Производни на 4"-заместен-9-деоксо-9а-аза-9а- хомоеритромицин а
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
WO2004096823A3 (en) Novel ketolide derivatives
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
CA2393757A1 (en) Cycloamine ccr5 receptor antagonists
EP1285660A4 (en) Zinc-supplementary compositions for oral administration
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
MX9207204A (es) Preparado farmaceutico y procedimiento para su fabricacion.
BG107407A (en) Novel polymorph v of torasemide
TNSN05247A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2005051349A3 (en) Pharmaceutical compositions of mirtazapine
WO2025162289A3 (zh) 一种pde4b抑制剂的晶型及其在医药上的用途

Legal Events

Date Code Title Description
HB1A Correction of owner name or address
HC1A Change of owner name
HC1A Change of owner name
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130122